目的：比较替吉奥与卡培他滨分别联合奥沙利铂治疗晚期结直肠癌的临床疗效。方法随机将患者分为实验组（替吉奥联合奥沙利铂，n＝21）和对照组（奥沙利铂联合卡培他滨，n＝20），分析比较2组的客观有效率（ ORR）、疾病控制率（ DCR）、中位进展期（ mTTP）及不良反应发生率。结果 ORR、DCR和mTTP比较，2组差异均无统计学意义（P＞0．05），不良反应中实验组血小板减少发生率与手足综合征发生率均低于对照组，差异有统计学意义（P＜0．05）。结论替吉奥联合奥沙利铂方案是晚期结直肠癌患者化疗的较好选择。%Objective To compare the clinical efficacy of S-1 or capecitabine plus oxaliplatin respectively for advanced colorectal cancer.Methods Patitents were randomly divided into the experimental group (S-1 plus oxaliplatin,n=21)and the control group(capecitabine plus oxaliplatin,n=20),objective response rates(ORR),disease control rates(DCR),median time to progress ( mTTP) and side effects of the 2 groups were compared .Results ORR、DCR and mTTP of the 2 groups had no statistical difference(P>0.05),rates of thrombocytopenia and hand-foot syndrome of the experimental group were significantly lower than those of the control group(P<0.05).Conclusion S-1 plus oxaliplatin can be an effective strategy for patients with advanced colorectal cancer .
展开▼
